VSY Biotechnology GmbH has developed a new drug candidate, TR-C 19, to treat COVID-19. Studies have shown that TR-C 19 can neutralize the virus isolated under lab conditions. The drug is under review for use on voluntary COVID-19 patients and clinical trials. Health authorities have accelerated their evaluation of TR-C 19 considering the public health emergency conditions.

Dr. Ercan Varlibas, the Chairman of the Board of Directors of VSY Biotechnology GmbH said, “At VSY Biotechnology, we have completed many pioneering R&D projects by producing new technologies thanks to our R&D team and innovation power. Our TR-C 19 project is one of the most meaningful projects that we have been developing.”

Clinical and voluntary trials will be organized in partnership with SBU. The initial results of voluntary patient trials will be shared publicly in the coming weeks.